InvestorsHub Logo
Followers 122
Posts 17458
Boards Moderated 0
Alias Born 01/06/2014

Re: None

Wednesday, 07/03/2019 7:32:58 AM

Wednesday, July 03, 2019 7:32:58 AM

Post# of 425759
How confident are Amarin about getting FDA approval of label expansion?

Yesterday's PR:

These revised plans follow estimated record revenues for the quarter ended June 30, 2019 and assume expanded FDA labelling for Vascepa.



The last time I remember Amarin assuming anything was the Standard (not Priority) Review, which is part of Thero's 'under-assume / over-deliver' schtick.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News